About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
S
AL Amyloidosis Therapy and Targets in 2019: Bortezomib Remains Mainstay in Frontline, ASCT in Upfront Is Questionable, Targeted Therapies Offer Promise, IO to Be Proven
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Suzanne Lentzsch
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Suzanne Lentzsch
80 views
November 18, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Multiple Myeloma
12:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Non-Antibody Based Immune Therapy for Multiple Myeloma: T-Cell Thera…
Feat.
N. Shah
14:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Role of Autologous Stem Cell Transplant in Myeloma in 2019: ASCT Rem…
Feat.
M. Mateos
14:12
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Myeloma Bone Disease and Management: Optimal Imaging Supports Clinic…
Feat.
M. Drake
13:17
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
It's Time to Use MRD for Clinical Decision Making: MRD as a Sur…
Feat.
J. Wolf
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patien…
Feat.
T. Martin
14:24
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
AL Amyloidosis Therapy and Targets in 2019: Bortezomib Remains Mains…
Feat.
S. Lentzsch
14:43
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Induction Therapy for Newly Diagnosed Multiple Myeloma: What to Use …
Feat.
A. Nooka
08:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Phase 2 HORIZON Study of Melflufen in Relapsed/Refractory Multiple M…
Feat.
C. Maisel
08:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Primary Treatment of Light Chain Amyloidosis with Bortezomib, Lenali…
Feat.
I. Dialoupi
